GOTHENBURG, Sweden, November 10, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com.
GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2023 is now available on the company’s website, www.isofolmedical.com.
GOTHENBURG, Sweden, May 3, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–March 2023 is now available, in Swedish, on the company’s website, www.isofolmedical.com.
GOTHENBURG, Sweden, April 6, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2022 are now available, in Swedish, on the company’s website, www.isofolmedical.com.
GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr. Ulf Jungnelius M.D. and Isofol’s Board of Directors have agreed that Ulf will step down as CEO of Isofol on June 1, 2023. Isofol’s Board of Directors will take a decision regarding a new CEO once the company’s future has been determined.
GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Moreover, no predictive gene expressions for clinical response could be identified. Isofol is continuing its efforts to terminate the AGENT study in line with applicable ethical and regulatory requirements, complete the final study report for submission to regulatory agencies and prepare a manuscript for a scientific publication. Isofol is in parallel continuing to investigate possible future paths forward for the company.
GOTHENBURG, Sweden, November 11, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–September 2022 is now available on the company’s website, www.isofolmedical.com.
GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company’s annual report and corporate governance report for the financial year 2021 are now available on the company’s website, www.isofolmedical.com.
GOTHENBURG, Sweden, February 24, 2022 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s year-end report for January – December 2021 is now available on the company’s website, www.isofolmedical.com.
